Life science company Nanologica has secured an order worth approximately SEK 2 million for its silica-based purification media, NLAB Saga, according to a press release.

The customer is a manufacturer of peptide pharmaceuticals, and the order pertains to the evaluation of NLAB Saga at production scale.

"After working with this customer for an extended period, it is very satisfying to secure this order, which clearly demonstrates the customer's satisfaction with our product quality and their intent to evaluate it at production scale for inclusion in their manufacturing process. It is also encouraging that this order involves a particle size generally used by insulin manufacturers, further indicating that we will find demand for our various product types beyond those typically used for the purification of GLP-1 analogues," commented Nanologica CEO Andreas Bhagwani.